Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

Giuseppe Bronte, Antonio Russo, Kostantinos Papadimitriou, Rosario García Campelo, Christian Rolfo, Luis E. Raez, Noemí Reguart, Franco Silvestris

Risultato della ricerca: Article

12 Citazioni (Scopus)

Abstract

INTRODUCTION:The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting.AREAS COVERED:Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying SREs. In comparison with zoledronic acid, denosumab significantly delayed the time to first SRE by 17%.EXPERT OPINION:Current research on denosumab is addressed to prove the immunomodulator effect of this agent in humans. Other avenue of research is focused on its antitumor activity observed in some Phase III trials.
Lingua originaleEnglish
pagine (da-a)15-26
Numero di pagine12
RivistaExpert Opinion on Biological Therapy
Volume14
Stato di pubblicazionePublished - 2014

Fingerprint

zoledronic acid
Bone
Neoplasm Metastasis
Bone and Bones
Skeleton
Tumors
Neoplasms
RANK Ligand
Therapeutics
Diphosphonates
Immunologic Factors
Standard of Care
Research
Monoclonal Antibodies
Denosumab
Morbidity

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cita questo

Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. / Bronte, Giuseppe; Russo, Antonio; Papadimitriou, Kostantinos; Campelo, Rosario García; Rolfo, Christian; Raez, Luis E.; Reguart, Noemí; Silvestris, Franco.

In: Expert Opinion on Biological Therapy, Vol. 14, 2014, pag. 15-26.

Risultato della ricerca: Article

Bronte, G, Russo, A, Papadimitriou, K, Campelo, RG, Rolfo, C, Raez, LE, Reguart, N & Silvestris, F 2014, 'Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor', Expert Opinion on Biological Therapy, vol. 14, pagg. 15-26.
Bronte, Giuseppe ; Russo, Antonio ; Papadimitriou, Kostantinos ; Campelo, Rosario García ; Rolfo, Christian ; Raez, Luis E. ; Reguart, Noemí ; Silvestris, Franco. / Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. In: Expert Opinion on Biological Therapy. 2014 ; Vol. 14. pagg. 15-26.
@article{4695bdbc5e714ff2b5385fef13bf6287,
title = "Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor",
abstract = "INTRODUCTION:The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting.AREAS COVERED:Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying SREs. In comparison with zoledronic acid, denosumab significantly delayed the time to first SRE by 17{\%}.EXPERT OPINION:Current research on denosumab is addressed to prove the immunomodulator effect of this agent in humans. Other avenue of research is focused on its antitumor activity observed in some Phase III trials.",
author = "Giuseppe Bronte and Antonio Russo and Kostantinos Papadimitriou and Campelo, {Rosario Garc{\'i}a} and Christian Rolfo and Raez, {Luis E.} and Noem{\'i} Reguart and Franco Silvestris",
year = "2014",
language = "English",
volume = "14",
pages = "15--26",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor

AU - Bronte, Giuseppe

AU - Russo, Antonio

AU - Papadimitriou, Kostantinos

AU - Campelo, Rosario García

AU - Rolfo, Christian

AU - Raez, Luis E.

AU - Reguart, Noemí

AU - Silvestris, Franco

PY - 2014

Y1 - 2014

N2 - INTRODUCTION:The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting.AREAS COVERED:Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying SREs. In comparison with zoledronic acid, denosumab significantly delayed the time to first SRE by 17%.EXPERT OPINION:Current research on denosumab is addressed to prove the immunomodulator effect of this agent in humans. Other avenue of research is focused on its antitumor activity observed in some Phase III trials.

AB - INTRODUCTION:The skeleton is generally the primary, and sometimes the only, site of metastasis in patients with advanced solid tumors. Bone metastases are the most frequent cause of cancer-related pain and the origin of severe morbidity in patients. Among the treatment options available for the prevention of skeletal-related events (SREs) associated with bone metastasis, zoledronic acid, an antiresorptive treatment from the group of bisphosphonates, is currently the standard of care in this setting.AREAS COVERED:Zoledronic acid, together with denosumab (a monoclonal antibody against the receptor activator of nuclear factor kappa B ligand), is the most frequent approach for the prevention of cancer-related events in skeleton. This paper reviews several trials evaluating the efficacy of denosumab in comparison with zoledronic acid in patients with solid osteotropic tumors. In this setting of skeleton-invading cancers, denosumab was demonstrated to be superior to zoledronic acid in preventing or delaying SREs. In comparison with zoledronic acid, denosumab significantly delayed the time to first SRE by 17%.EXPERT OPINION:Current research on denosumab is addressed to prove the immunomodulator effect of this agent in humans. Other avenue of research is focused on its antitumor activity observed in some Phase III trials.

UR - http://hdl.handle.net/10447/99247

UR - http://informahealthcare.com/doi/abs/10.1517/14712598.2013.843667

M3 - Article

VL - 14

SP - 15

EP - 26

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -